Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Centamin holds outlook as production rises 2%

(Sharecast News) - Gold miner Centamin said its outlook for 2024 remained unchanged as it delivered annual production in line with guidance despite local inflationary cost pressures. The company on Thursday said gold production rose 2% to 450,058 ounces and said its all-in sustaining costs of $1,205 per ounce sold were a guidance-beating 14% improvement on 2022.

Adjusted core earnings rose 25% to $398 million, at a 45% margin, up from 40% in 2022.

Annual capital expenditure of $204m was below guidance of $272m due to cost savings, lower capitalisation of costs and changes to equipment rebuild schedules.

Centamin said its Sukari mine in Egypt had been repositioned towards consistently delivering 500,000 ounces per annum over long-term and said connection to the grid using solar power would take more costs out of the business.

A final dividend of 2 cents a share was declared, equating to $23m.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.